Entering text into the input field will update the search result below

Bayer says late-stage prostate cancer study for Nubeqa met main goal

Dec. 03, 2021 7:12 AM ETBayer Aktiengesellschaft (BAYRY), BAYZFBy: Dulan Lokuwithana, SA News Editor

Cancer Outbreak

wildpixel/iStock via Getty Images

  • Nubeqa (darolutamide), developed by Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) and Orion Corporation, has met the primary endpoint in a Phase 3 trial involving patients with hormone-sensitive prostate cancer ((mHSPC)).
  • In the ARASENS trial, darolutamide in combination with docetaxel

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.